Granted Patent
B2
US 12,365,713 · App. 17/693,956 · Granted Jul 22, 2025
Fusion protein comprising IL13
Inventors:
Niels Eijkelkamp (Utrecht, NL); Cornelis Erik Hack (Diemen, NL); Judith Prado Sanchez (Utrecht, NL); Jelena Popov-Čeleketić (Utrecht, NL); Sabine Versteeg (Tiel, NL)
Assignee:
Synerkine Pharma B.V.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention is concerned with a fusion protein comprising interleukin 13 and a regulatory cytokine, for example, an interleukin chosen from interleukin 4, interleukin 10, interleukin 27, interleukin 33, transforming growth factor beta 1, transforming growth factor beta 2, and interleukin 13, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of a condition characterized by pathological pain, chronic pain, neuro-inflammation and/or or neurodegeneration.
Claims (35)
1. A fusion protein comprising:
(a) a first interleukin that is IL13 and comprises the amino acid sequence of SEQ ID NO: 2 or any one of SEQ ID NOs: 9-15;
(b) a linker; and
(c) a second interleukin that
is IL4 and comprises the amino acid sequence of SEQ ID NO: 1 or any one of SEQ ID NOs: 26-28;
wherein a C terminus of the first interleukin is joined to an N terminus of the linker and a C terminus of the linker is joined to an N terminus of the second interleukin, or a C terminus of the second interleukin is joined to the N terminus of the linker and the C terminus of the linker is joined to an N terminus of the first interleukin.
2. The fusion protein of claim 1 , wherein the linker comprises the amino acid sequence of SEQ ID NO: 3.
3. The fusion protein of claim 1 , wherein the C terminus of the first interleukin is joined to the N-terminus of the linker, and the C terminus of the linker is joined to the N terminus of the second interleukin.
4. The fusion protein of claim 1 , wherein the C terminus of the second interleukin is joined to the N terminus of the linker and the C-terminus of the linker is joined to the N terminus of the first interleukin.
5. The fusion protein of claim 1 , wherein the fusion protein further comprises one or more chemical modifications, wherein the one or more chemical modifications comprise glycosylation, fucosylation, sialylation, or pegylation.
6. A pharmaceutical composition comprising the fusion protein of claim 1 and a pharmaceutically-acceptable excipient.
7. The pharmaceutical composition of claim 6 , wherein the pharmaceutical composition is in a unit dosage form.
8. A fusion protein comprising an amino acid sequence that is SEQ ID NO: 16.
9. A fusion protein comprising:
(a) a first cytokine that is IL13 and comprises the amino acid sequence of SEQ ID NO: 2 or any one of SEQ ID NOs: 9-15;
(b) a second cytokine that
is IL4 and comprises the amino acid sequence of SEQ ID NO: 1 or any one of SEQ ID NOs: 26-28;
and:
(c) a linker, wherein the first cytokine is joined to the second cytokine via the linker.
10. A fusion protein comprising an amino acid sequence that is SEQ ID NO: 4.
11. The fusion protein of claim 10 , wherein the fusion protein consists of the amino acid sequence of SEQ ID NO: 4.
12. The fusion protein of claim 8 , wherein the fusion protein consists of the amino acid sequence of SEQ ID NO: 16.
13. The fusion protein of claim 2 , wherein the C terminus of the first interleukin is joined to the N-terminus of the linker, and the C terminus of the linker is joined to the N terminus of the second interleukin.
14. The fusion protein of claim 2 , wherein the C terminus of the second interleukin is joined to the N terminus of the linker and the C-terminus of the linker is joined to the N terminus of the first interleukin.
15. The fusion protein of claim 1 , wherein the fusion protein is glycosylated.
16. The fusion protein of claim 1 , wherein the first interleukin that is IL13 comprises the amino acid sequence of SEQ ID NO: 14.
17. The fusion protein of claim 1 , wherein the first interleukin that is IL13 comprises the amino acid sequence of SEQ ID NO: 2.
18. The fusion protein of claim 1 , wherein the second interleukin that is IL4 comprises the amino acid sequence of SEQ ID NO: 1.
19. The fusion protein of claim 1 , wherein the first interleukin that is IL13 comprises the amino acid sequence of SEQ ID NO: 14 and the second interleukin that is IL4 comprises the amino acid sequence of SEQ ID NO: 1.
20. The fusion protein of claim 1 , wherein the first interleukin that is IL13 comprises the amino acid sequence of SEQ ID NO: 2 and the second interleukin that is IL4 comprises the amino acid sequence of SEQ ID NO: 1.
21. The fusion protein of claim 9 , wherein the first interleukin that is IL13 comprises the amino acid sequence of SEQ ID NO: 14.
22. The fusion protein of claim 9 , wherein the first interleukin that is IL13 comprises the amino acid sequence of SEQ ID NO: 2.
23. The fusion protein of claim 9 , wherein the second interleukin that is IL4 comprises the amino acid sequence of SEQ ID NO: 1.
24. The fusion protein of claim 9 , wherein the first interleukin that is IL13 comprises the amino acid sequence of SEQ ID NO: 14 and the second interleukin that is IL4 comprises the amino acid sequence of SEQ ID NO: 1.
25. The fusion protein of claim 9 , wherein the first interleukin that is IL13 comprises the amino acid sequence of SEQ ID NO: 2 and the second interleukin that is IL4 comprises the amino acid sequence of SEQ ID NO: 1.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 16, 2025
From: EIJKELKAMP, NIELS; HACK, CORNELIS ERIK; SANCHEZ, JUDITH PRADO; POPOV-CELEKETIC, JELENA; VERSTEEG, SABINE
To: UMC UTRECHT HOLDING B.V.
Reel/Frame 071421/0604 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 16, 2025
From: UMC UTRECHT HOLDING B.V.
To: SYNERKINE PHARMA B.V.
Reel/Frame 071421/0630 →
Priority Claims (2)
NL 2022982
· Apr 19, 2019
· national
NL 2022984
· Apr 19, 2019
· national
Continuity (3)
Continuation
PCTEP2020060910
· Apr 17, 2020
References Cited (330)
US 4399216A
· Axel et al.
· 1983
[cited by applicant]
US 4634665A
· Axel et al.
· 1987
[cited by applicant]
US 5179017A
· Axel et al.
· 1993
[cited by applicant]
US 5567611A
· Ralph et al.
· 1996
[cited by applicant]
US 5601815A
· Powrie et al.
· 1997
[cited by applicant]
US 5951973A
· Lee et al.
· 1999
[cited by applicant]
US 5986059A
· Shanafelt et al.
· 1999
[cited by applicant]
US 6428985B1
· Bromberg et al.
· 2002
[cited by applicant]
US 6630576B2
· Debinski
· 2003
[cited by applicant]
US 7261882B2
· Watkins
· 2007
[cited by applicant]
US 7749490B2
· Sommer et al.
· 2010
[cited by applicant]
US 8247385B2
· Yoo
· 2012
[cited by applicant]
US 8349332B2
· Chang et al.
· 2013
[cited by applicant]
US 8404814B2
· Neri et al.
· 2013
[cited by applicant]
US 9738696B2
· Garcia et al.
· 2017
[cited by applicant]
US 20050053579A1
· Galipeau et al.
· 2005
[cited by applicant]
US 20060246032A1
· Strom et al.
· 2006
[cited by applicant]
US 20100028296A1
· Chavez et al.
· 2010
[cited by applicant]
US 20120164101A1
· Galipeau et al.
· 2012
[cited by applicant]
US 20130316404A1
· Roers et al.
· 2013
[cited by applicant]
US 20140314712A1
· Van Roon et al.
· 2014
[cited by applicant]
US 20200095301A1
· Garcia et al.
· 2020
[cited by applicant]
US 20200158716A1
· Shalek et al.
· 2020
[cited by applicant]
US 20200377568A1
· Vogelaar et al.
· 2020
[cited by applicant]
US 20210024631A1
· Kley et al.
· 2021
[cited by applicant]
US 20210261639A1
· Van Roon et al.
· 2021
[cited by applicant]
US 20220106373A1
· Mumm
· 2022
[cited by applicant]
US 20220143145A1
· Eijkelkamp et al.
· 2022
[cited by applicant]
US 20220378877A1
· Petri, Jr. et al.
· 2022
[cited by applicant]
US 20220403026A1
· Butte et al.
· 2022
[cited by applicant]
US 20230203117A1
· Gorby et al.
· 2023
[cited by applicant]
US 20230210953A1
· Mumm
· 2023
[cited by applicant]
US 20230242615A1
· Li et al.
· 2023
[cited by applicant]
US 20230272094A1
· Kastelein et al.
· 2023
[cited by applicant]
US 20230279125A1
· Kastelein et al.
· 2023
[cited by applicant]
US 20230279126A1
· Kastelein et al.
· 2023
[cited by applicant]
US 20230287075A1
· Mumm
· 2023
[cited by applicant]
US 20230340052A1
· Mumm
· 2023
[cited by applicant]
US 20230357414A1
· Vivona et al.
· 2023
[cited by applicant]
US 20230365696A1
· Kastelein et al.
· 2023
[cited by applicant]
US 20230391891A1
· Kastelein et al.
· 2023
[cited by applicant]
US 20240026014A1
· Kastelein et al.
· 2024
[cited by applicant]
US 20240052006A1
· Hubbell et al.
· 2024
[cited by applicant]
US 20240076331A1
· Lu
· 2024
[cited by applicant]
US 20240166754A1
· Kastelein et al.
· 2024
[cited by applicant]
US 20240181009A1
· Gonzalez et al.
· 2024
[cited by applicant]
US 20240197832A1
· Hu et al.
· 2024
[cited by applicant]
CN 1074243A
· 1993
[cited by applicant]
CN 1382158A
· 2002
[cited by applicant]
CN 1922204A
· 2007
[cited by applicant]
CN 101557817A
· 2009
[cited by applicant]
CN 104136457A
· 2014
[cited by applicant]
CN 106139125A
· 2016
[cited by applicant]
CN 107683289A
· 2018
[cited by applicant]
CN 108129574A
· 2018
[cited by applicant]
EP 0923387A2
· 1999
[cited by applicant]
EP 1731531A2
· 2006
[cited by applicant]
EP 2776460B1
· 2018
[cited by applicant]
JP 6284482B2
· 2018
[cited by applicant]
JP 6527925B2
· 2019
[cited by applicant]
WO WO9319770A1
· 1993
[cited by applicant]
WO WO9404680A1
· 1994
[cited by applicant]
WO WO9503411A1
· 1995
[cited by applicant]
WO WO9749434A2
· 1997
[cited by applicant]
WO WO9833516A1
· 1998
[cited by applicant]
WO WO0027881A3
· 2000
[cited by applicant]
WO WO0110912A1
· 2001
[cited by applicant]
WO WO2006079169A1
· 2006
[cited by applicant]
WO WO2010040105A2
· 2010
[cited by applicant]
WO WO2011108937A1
· 2011
[cited by applicant]
WO WO2013070076A1
· 2013
[cited by applicant]
WO WO2014074186A2
· 2014
[cited by applicant]
WO WO2018112266A1
· 2018
[cited by applicant]
WO WO2018182935A1
· 2018
[cited by applicant]
WO WO2018202876A1
· 2018
[cited by applicant]
WO WO2019232523A1
· 2019
[cited by applicant]
WO WO2020181235A1
· 2020
[cited by applicant]
WO WO2020212602A1
· 2020
[cited by applicant]
WO WO2022025643A1
· 2022
[cited by applicant]
WO WO2022223001A1
· 2022
[cited by applicant]
WO WO2023030489A1
· 2023
[cited by applicant]
WO WO2023075623A1
· 2023
[cited by applicant]
WO WO2023144393A1
· 2023
[cited by applicant]
WO WO2023172868A1
· 2023
[cited by applicant]
WO WO2023183816A2
· 2023
[cited by applicant]
WO WO2023230163A1
· 2023
[cited by applicant]
WO WO2024094755A1
· 2024
[cited by applicant]
Bork. Powers and Pitfalls in Sequence Analysis: The 70% Hurdle. Genome Research, 2000, 10:398-400 (Year: 2000).
[cited by examiner]
Greenspan et al. 1999. Defining epitopes: It's not as easy as it seems; Nature Biotechnology, 17:936-937 (Year: 1999).
[cited by examiner]
Bowie et al. Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions. Science, 1990, 247:1306-1310 (Year: 1990).
[cited by examiner]
Burgess et al. Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single L…
[cited by examiner]
Lazar et al. Transforming Growth Factor alpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities. Mol. Cell. Biol., 8:1247-1252, 1988 (Year: 1988).
[cited by examiner]
Castillo-Guzman et al.: Complex regional pain syndrome (CRPS), a review. Medicina Universitaria. 17(67):114-121 (2015).
[cited by applicant]
EP20722497.3 European Communication dated Apr. 8, 2024.
[cited by applicant]
U.S. Appl. No. 17/192,183 Office Action dated Nov. 7, 2023.
[cited by applicant]
Abrahamsen, B. et al., “The cell and molecular basis of mechanical, cold, and inflammatory pain,” Science, 2008;321(5889):702-5.
[cited by applicant]
Anders, S. et al., “HTSeq—a Python framework to work with high-throughput sequencing data,” Bioinformatics, 2015;31(2):166-9.
[cited by applicant]
Sasaguri, Tomoko, et al. “Interleukin-27 controls basal pain threshold in physiological and pathological conditions.” Scientific reports 8.1 (2018): 1-13.
[cited by applicant]
Sasaki, K. et al. “IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit,” European Journal of Immunology, 2008, vol. 38, No. 10 , pp. 2865-2873.
[cited by applicant]
Atkins, M. B. et al., “Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy,” J Clin Oncol, 1992, vol. 10, pp. 1802-1809.
[cited by applicant]
Backonja, M.M. et al., “Altered cytokine levels in the blood and cerebrospinal fluid of chronic pain patients,” J Neuroimmunol., 2008;195(1-2):157-163.
[cited by applicant]
Bottros, MM, et al., “Current perspectives on intrathecal drug delivery, ”J Pain Res, 2014;7:615-26.
[cited by applicant]
Breivik, H, et al., “Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment,” Eur J Pain 2006;10:287-333.
[cited by applicant]
Breivik, H, et al., “The individual and societal burden of chronic pain in Europe: the case for strategic prioritization and action to improve knowledge and availability of appropriate care,” BMC Public Health, 2013;13:…
[cited by applicant]
Busch-Dienstfertig M., et al., “IL-4, JAK-STAT signaling, and pain,” JAKSTAT, 2013;2(4):e27638.
[cited by applicant]
Cavaillon, J., “PRO-versus Anti-Inflammatory Cytokines: Myth or Reality”, Cellular and Molecular Biology, 2001, vol. 47, No. 4, pp. 1-8.
[cited by applicant]
Chaplan, S.R. et al. “Quantitative assessment of tactile allodynia in the rat paw,” J Neurosci Methods, 1994;53:55-63.
[cited by applicant]
Chen G, et al., “Microglia in Pain: Detrimental and Protective Roles in Pathogenesis and Resolution of Pain,” Neuron 2018;100:1292-311.
[cited by applicant]
Chen H, et al., “IL-10 Promotes Neurite Outgrowth and Synapse Formation in Cultured Cortical Neurons after the Oxygen-Glucose Deprivation via JAK1/STAT3 Pathway,” Sci Rep. 2016;6:30459.
[cited by applicant]
Chomarat, P. et al., “Differential effects of interleukins 10 and 4 on the production of interleukin-6 by blood and synovium monocytes in rheumatoid arthritis,” Arthritis Rheum, 1995, 38:1046-54.
[cited by applicant]
Cunningham, F. et al., “Ensembl 2015.” Nucleic acids research, 2015;43:D662-9.
[cited by applicant]
Dahlhammer J, et al., “Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults—United States, 206,” Morbidity and Mortality Weekly Report (MMWR), 2018;67:1001-6.
[cited by applicant]
De Jong, et al., “Pan-DR-Binding Hsp60 Self Epitopes Induce and Interleukin-10-Mediated Immune Response in Rheumatoid Arthritis”, Arthritis & Rheumatism, 2009, vol. 60, No. 7, pp. 1966-1976.
[cited by applicant]
De Oliveira, et al. “Cytokines and Pain,” Rev Bras Anestesiol, 2011;61(2):255-265.
[cited by applicant]
Ding, et al., “A Single Amino Acid Determines the Immunostimulatory Activity of Interleukin 10”, J. Exp. Med., 2000, vol. 191, No. 2, pp. 213-223.
[cited by applicant]
Durocher, et al., “High-level an high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells”, Nucleic Acids Research, 2002, vol. 30, No. 2e9, pp. 1-9.
[cited by applicant]
Echeverry, S. et al. “Transforming growth factor-β1 impairs neuropathic pain through pleiotropic effects.” Molecular pain, 2009;1744-8069.
[cited by applicant]
Eijkelkamp, N. et al., “IL4-10 Fusion Protein is a Novel Drug to Treat Persistent Inflammatory Pain” The Journal of Neuroscience, 2016;36(28):7353-7363.
[cited by applicant]
Eijkelkamp, N. et al., “A role for Piezo2 in EPAC1-dependent mechanical allodynia,” Nat Commun, 2013;4(1682).
[cited by applicant]
Eijkelkamp, N. et al., “GRK2: a novel cell-specific regulator of severity and duration of inflammatory pain,” J Neurosci., 2010;30(6):2138-49.
[cited by applicant]
Feldmann, M. et al., “Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?” Annu Rev Immunol., 2001;19:163-196.
[cited by applicant]
Gillies, S. et al., “Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer,” Cancer Immunol Immunother, 2002, vol. 51, pp. 449-460.
[cited by applicant]
Grace, P.M. et al., “Pathological pain and the neuroimmune interface,” Nat Rev Immunol, 2014;14(4):217-231.
[cited by applicant]
Guichelaar, et al., “Cartilage proteoglycan-specific T cells as vectors of immunomodulatory biologicals in chronic proteoglycan-induced arthritis”, Molecular Immunology, 2008;45:3526-3535.
[cited by applicant]
Hagenacker, T. et al., “Sensitization of voltage activated calcium channel currents for capsaicin in nociceptive neurons by tumor-necrosis-factor-alpha,” Brain Res Bull, 2010;81(1):157-163.
[cited by applicant]
Shanafelt, A.B. et al. “An immune cell-selective interleukin 4 agonist.” Proceedings of the National Academy of Sciences, 1998;95(16): 9454-9458.
[cited by applicant]
Hao, S. et al., “HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain,” Mol Pain, 2006;2:6.
[cited by applicant]
Hargreaves et al., “A new and sensitive method for measuring thermal nociception incutaneous hyperalgesia,” Pain, 1988;32(1):77-88.
[cited by applicant]
Hartgring, S.A.Y., “Role of IL-7 and TSLP in immunopathology of (rheumatoid) arthritis”, University Medical Center Utrecht, 2009, pp. 1-185.
[cited by applicant]
Hemmati, S. et al., “Polypharmacological Cell-Penetrating Peptides from Venomous Marine Animals Based on Immunomodulating, Antimicrobial, and Anticancer Properties,” Mar Drugs. 2022;20(12):763.
[cited by applicant]
Shen, K.F, et al., “Interleukin-10 down-regulates voltage gated sodium channels in rat dorsal root ganglion neurons,” Exp Neurol, 2013;247:466-475.
[cited by applicant]
Henikoff, et al., “Amino acid substitution matrices from protein blocks”, PNAS, 1992, vol. 89, pp. 10915-10919.
[cited by applicant]
Hernangomez, M. et al., “CD200R1 agonist attenuates glial activation, inflammatory reactions, and hypersensitivity immediately after its intrathecal application in a rat neuropathic pain model,” J Neuroinflammation, 201…
[cited by applicant]
Shi, et al., “Interleukin-4 protects from chemotherapy-induced peripheral neuropathy in mice modal via the stimulation of IL-4/STAT6 signaling” Acta Cir Bras, 2018;33(6): 491-498.
[cited by applicant]
Huhn, R. D. et al., “Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers,” Clin Pharmacol Ther, 1997, vol. 62, No. 2, pp. 171-180.
[cited by applicant]
Hwang, S.Y. et al., “IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via VF-kB-and PI3-kinase/Akt-dependent pathways” Arthritis Research & Therapy, 2004, vol. 6, No. 2, pp. R120-R1…
[cited by applicant]
International Search Report, PCT/EP2020/060910, issued Jun. 30, 2020.
[cited by applicant]
International Search Report, PCT/EP2020/060914, issued Jul. 10, 2020.
[cited by applicant]
International Search Report, PCT/NL2012/050790, issued Mar. 8, 2013.
[cited by applicant]
Jansen, et al., “Protective Abilities of Interleukin-10 in Case of Blood-Induced Joint Damage” University Medical Center Utrecht, 2008, pp. S27.
[cited by applicant]
Jansen, et al., “Interleukin-10 Projects Against Blood-Induced Joint Damage”, Rheumatology & Clinical Immunology, University Medical Center Utrecht, 2007, pp. C116.
[cited by applicant]
Jansen, et al., “Protective Abilities of Interleukin-10 in Blood-Induced Cartilage Damage,” University Medical Center Utrecht, 2006, pp. S96.
[cited by applicant]
Jansen, N.W.D. et al., “Interleukin-10 protects against blood-induced joint damage”, British Journal of Haematology, 2008, vol. 142, pp. 953-961.
[cited by applicant]
Ji, R.R. et al., “Pain regulation by non-neuronal cells and inflammation,” Science, 2016;354(6312):572-577.
[cited by applicant]
Ji, R.R. et al., “Glia and pain: is chronic pain a gliopathy?,” Pain, 2013; 154(Suppl 1):S10-28.
[cited by applicant]
Johannes, C.B. et al., “The prevalence of chronic pain in United States adults: results of an Internet-based survey,” J Pain, 2010;11:1230-9.
[cited by applicant]
Joosten, L. et al., “Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction,” Arthritis Rheum, 1997, vol. …
[cited by applicant]
Junttila, et al., “Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines” Nat Chem Bio., 2012;8(12): 990-998.
[cited by applicant]
Khoonsari, P.E. et al., “The human CSF pain proteome,” J Proteomics, 2019;190:67-76.
[cited by applicant]
Kiguchi, et al., “Peripheral administration of interleukin-13 reverses inflammatory macrophage and tactile allodynia in mice with partial sciatic nerve ligation” Journal of Pharmacology Sciences, 2017;133:S53-S56.
[cited by applicant]
Kim, H. et al., “The current state of the osteoarthritis drug development pipeline: a comprehensive narrative review of the present challenges and future opportunities,” Ther Adv Musculoskelet Dis., 2022;14:1-28.
[cited by applicant]
Kraus, J. et al., “Regulation of mu-opioid receptor gene transcription by interleukin-4 and influence of an allelic variation within a STAT6 transcription factor binding site,” J Biol Chem, 2001;276(47):43901-43908.
[cited by applicant]
Kreitman, et al., “Site-Specific Conjugation to Interleukin 4 Containing Mutated Cysteine Residues Produces Inerleukin 4-Toxin Conjugates with Improved Binding an Activity” Biochemistry, 1994;33:11637-11644.
[cited by applicant]
Krukowski, K et al., “CD8+ T Cells and Endogenous IL-10 Are Required for Resolution of Chemotherapy-Induced Neuropathic Pain,” J Neurosci, 2016;36(43):11074-11083.
[cited by applicant]
Kruse, et al., “Site-directed mutagenesis reveals the importance of disulfide bridges and aromatic residues for structure and prolifeative activity of human Interleukin-4,” Federation of European Biochemical Societies, …
[cited by applicant]
Kruse, et al., “Two distinct functional sites of human interleukin 4 are identified by variants impaired in either receptor binding or receptor activation” The EMBO Journal, 1993, vol. 12, No. 13, pp. 5121-5129.
[cited by applicant]
Lauw, et al., “Proinflammatory Effects of IL-10 During Human Endotoxemia”, The Journal of Immunology, 2000, 165:2783-2789.
[cited by applicant]
Ledeboer, A. et al., “Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats,” Brain Behav Immun., 2007;21(5):68…
[cited by applicant]
Lee, M. et al., “Prevention of autoimmune insulitis by delivery of a chimeric plasmid encoding interleukin-4 and interleukin-10,” Journal of Controlled Release, 2003;88(2):333-342.
[cited by applicant]
Lees, J.G. et al., “Immunotherapy targeting cytokines in neuropathic pain,” Frontiers in pharmacology, 2013;4(142):1-4.
[cited by applicant]
Lemmer, S, et al., “Enhanced spinal neuronal responses as a mechanism for the increased nociceptive sensitivity of interleukin-4 deficient mice,” Exp Neurol., 2015;271:198-204.
[cited by applicant]
Letzelter, F. et al., “The interleukin-4 site-2 epitope determining binding of the common receptor γ chain.” Eur. J. Biochem., 1998;257:11-20.
[cited by applicant]
Li, P. et al., “A fusion cytokine coupling GMCSF to IL9 induces heterologous receptor clustering and STAT1 hyperactivation through JAK2 promiscuity,” PLoS One, 2013;8(7):e69405.
[cited by applicant]
Lima, R. et al., “Systemic Interleukin-4 Administration after Spinal Cord Injury Modulates Inflammation and Promotes Neuroprotection,” Pharmaceuticals, 2017;10(4):1-16.
[cited by applicant]
Love, M.I. et al., “Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2,” Genome Biol., 2014;15(12):550.
[cited by applicant]
Maini, R.N. et al., “rHuIL-10 in subjects with active rheumatoid arthritis: a phase I and cytokine response study [abstract],” Arthritis Rheum, 1997;40(Suppl. 9):S224.
[cited by applicant]
Marie, C. et al., “IL-10 and IL-4 synergize with TNF-alpha to induce IL-1ra production by human neutrophils,” Cytokine, 1996;8:147-51.
[cited by applicant]
McKelvey, R. et al., “Neuropathic pain is constitutively suppressed in early life by anti-inflammatory neuroimmune regulation,” J Neurosci, 2015;35(2):457-466.
[cited by applicant]
Mika, J. et al., “Importance of glial activation in neuropathic pain,” Eur J Pharmacol, 2013;716(1-3):106-119.
[cited by applicant]
Milligan, E.D. et al., “Spinal interleukin-10 therapy to treat peripheral neuropathic pain,” Neuromodulation, 2012;15(6):520-526.
[cited by applicant]
Moraga, I. et al., “Synthekines are surrogate cytokine and growth factor agonists that compel signaling through non-natural receptor dimers,” Elife, 2017;6:e22882.
[cited by applicant]
Moraga, I. et al., “Multifarious determinants of cytokine receptor signaling specificity,” Adv Immunol, 2014;121:1-39.
[cited by applicant]
Morrison, B.W. et al., “A Receptor Binding Domain of Mouse Interleukin-4 Defined by a Solid-phase Binding Assay in in Vitro Mutagenesis”, The Journal of Biological Chemistry, 1992, vol. 267, No. 17, Issue of Jun. 15, pp…
[cited by applicant]
Nassar, M.A. et al., “Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain,” PNAS, 2004;101(34):12706-11.
[cited by applicant]
Ng, S. et al., “Concise review: engineering the fusion of cytokines for the modulation of immune cellular responses in cancer and autoimmune disorders,” Stem Cells Transl Med, 2015;4(1):66-73.
[cited by applicant]
Nicola, N. A. et al., “General Classes and Functions of Four-Helix Bundle Cytokines”, Advanced in Protein Chemistry, 1999, vol. 52, pp. 1-65.
[cited by applicant]
Nie, B, et al., “AKAP150 involved in paclitaxel-induced neuropathic pain via inhibiting CN/NFAT2 pathway and downregulating IL-4,” Brain Behav Immun., 2017;68:158-168.
[cited by applicant]
Old, E.A, et al., “The role of glia in the spinal cord in neuropathic and inflammatory pain,” Handb Exp Pharmacol., 2015;227:145-70.
[cited by applicant]
Spangler, J.B. et al., “A strategy for the selection of monovalent antibodies that span protein dimer interfaces,” Journal of Biological Chemistry, 2019;294(38):13876-13886.
[cited by applicant]
Pils, M.C. et al., “Monocytes/macrophages and/or neutrophils are the target of IL-10 in the LPS endotoxemia model,” Eur J Immunol, 2010;40(2):443-448.
[cited by applicant]
Popov-Celeketic, J. et al., “Local and Slow Release of IL4-10 Synerkine as a Disease Modifying Therapy for Osteoarthritis,” Osteoarthritis and Cartilage, 2016;24:S532.
[cited by applicant]
Powrie, F. et al., “Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo,” Eur J Immunol, 1993, vol. 23, pp. 2223-2229.
[cited by applicant]
Prado, J. et al., “A fusion protein of IL4 and IL10 resolves chronic inflammatory pain” Abstracts of the 5th European Congress of Immunology—ECI (2018) p. 357.
[cited by applicant]
Prado, J. et al., “Fusion Proteins of Anti-Inflammatory cytokines to Treat Chemotherapy-Induced Neuropathy” Pain In Europe XI, 11th Congress of The European Pain Federation EFIC Abstract Book (2019) p. 312.
[cited by applicant]
Prado, J. et al., “Development of Recombinant Proteins to Treat Chronic Pain,” J Vis Exp., 2018;134(e57071).
[cited by applicant]
Prado, J. et al., “Fusion Proteins of Anti-Inflammatory cytokines to Treat Chemotherapy-Induced Neuropathy” EFIC ePoster, University Medical Center Utrecht, 2016.
[cited by applicant]
Prasad, P. et al., “Rheumatoid arthritis: advances in treatment strategies,” Mol Cell Biochem. 2023;478(1):69-88.
[cited by applicant]
Pricop, L. et al., “Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines,” J Immunol, 2001, vol. 166, pp. 531-537.
[cited by applicant]
Pulles, A.E., et al. “A fusion protein of interleukin-4 and interleukin-10 protects against blood-induced cartilage damage in vitro and in vivo.” Osteoarthritis and Cartilage, 2016;24:S505.
[cited by applicant]
Punnonen, J. et al., “IL-10 and viral IL-10 prevent IL-4-induced IgE synthesis by inhibiting the accessory cell function of monocytes,” J Immunol, 1993, vol. 151, pp. 1280-1289.
[cited by applicant]
Pustjens, M.F., et al. “IL4-10 synerkine induces direct and indirect structural cartilage repair in osteoarthritis.” Osteoarthritis and Cartilage, 2016;24:S532.
[cited by applicant]
Rafei, M. et al., “A granulocyte-macrophage colony-stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties,” Nature medicine, 2009;15(9):1038-1045.
[cited by applicant]
Raoof, R. et al., “Divergent roles of immune cells and their mediators in pain,” Rheumatology (Oxford), 2018;57(3):429-440.
[cited by applicant]
Ray, P. et al., “Comparative transcriptome profiling of the human and mouse dorsal root ganglia: an RNA-seq-based resource for pain and sensory neuroscience research,” Pain, 2018;159(7):1325-1345.
[cited by applicant]
Ren, Y. et al., “Therapeutic effects of histone deacetylase inhibitors in a murine asthma model,” Inflammation Research, 2016;65:995-1008.
[cited by applicant]
Ren, K. et al., “Interactions between the immune and nervous systems in pain,” Nat Med, 2010;16(11):1267-1276.
[cited by applicant]
Rijsdijk, M. et al., “The effects of glucocorticoids on neuropathic pain: a review with emphasis on intrathecal methylprednisolone acetate delivery,” Anesth Analg, 2014;118:1097-112.
[cited by applicant]
Rijsdijk, M. et al., “No beneficial effect of intrathecal methylprednisolone acetate in postherpetic neuralgia patients,” Eur J Pain, 2013;17:714-23.
[cited by applicant]
Ripple, M.J. et al., “Immunomodulation with IL-4R alpha antisense oligonucleotide prevents respiratory syncytial virus-mediated pulmonary disease,” J Immunol., 2010;185(8):4804-11.
[cited by applicant]
Risso, D. et al., “Normalization of RNA-seq data using factor analysis of control genes or samples.” Nature biotechnology, 2014, vol. 32, No. 9, pp. 896-902.
[cited by applicant]
Sauer, B. et al., “Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1,” PNAS, 1988;85(14):5166-70.
[cited by applicant]
Schaible, H.G. et al., “Nociceptive neurons detect cytokines in arthritis,” Arthritis Res Ther., 2014;16:470.
[cited by applicant]
Scholz J, et al., “The neuropathic pain triad: neurons, immune cells and glia,” Nat Neurosci, 2007;10:1361-8.
[cited by applicant]
Söderberg, O. et al., “Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay,” Methods, 2008;45(3):227-32.
[cited by applicant]
Search Report and Written Opinion for Dutch Patent Application No. NL/2022982 issued Apr. 19, 2019.
[cited by applicant]
Search Report and Written Opinion for Dutch Patent Application No. NL/2022984 issued Apr. 19, 2019.
[cited by applicant]
Serhan, C.N. et al., “Resolution of inflammation: state of the art, definitions and terms,” FASEB J, 2007;21:325-32.
[cited by applicant]
Shao, Q. et al., “IL-10 and IL-1beta mediate neuropathic-pain like behavior in the ventrolateral orbital cortex,” Neurochem Res, 2015;40(4):733-739.
[cited by applicant]
Shields, S.D, et al., “Nav1.8 expression is not restricted to nociceptors in mouse peripheral nervous system,” Pain, 2012;153(10):2017-2030.
[cited by applicant]
Soderquist, R.G. et al., “Release of plasmid DNA-encoding IL-10 from PLGA microparticles facilitates long-term reversal of neuropathic pain following a single intrathecal administration,” Pharm Res, 2010;27(5):841-854.
[cited by applicant]
Steen-Louws, C, et al., “IL4-10 fusion protein has chondroprotective, anti-inflammatory and potentially analgesic effects in the treatment of osteoarthritis,” Osteoarthritis Cartilage, 2018, vol. 26, pp. 1127-1135.
[cited by applicant]
Stone, L.S. et al., “The pain of antisense: in vivo application of antisense oligonucleotides for functional genomics in pain and analgesia,” Adv Drug Deliv Rev, 2003;55(8):1081-1112.
[cited by applicant]
Te Velde, A.A. et al., “IL-10 stimulates monocyte Fc gamma R surface expression and cytotoxic activity. Distinct regulation of antibody-dependent cellular cytotoxicity by IFN-gamma, IL-4, and IL-10,” J Immunol, 1992, vo…
[cited by applicant]
Steen-Louws, et al., “IL4-10 fusion protein: a novel immunoregulatroy drug combining activities of interleukin 4 and interleukin 10,” Clinical & Experimental Immunology, The Journal of Translational Immunology, 2018;195…
[cited by applicant]
Thom, G. et al., “Probing a protein-protein interaction by in vitro evolution,” PNAS, 2006;103:7619-24.
[cited by applicant]
Toma, W. et al., “Effects of paclitaxel on the development of neuropathy and affective behaviors in the mouse,” Neuropharmacology, 2017;117:305-15.
[cited by applicant]
Uceyler, N. et al., “Differential expression patterns of cytokines in complex regional pain syndrome,” Pain, 2007;132(1-2):195-205.
[cited by applicant]
Uceyler, N. et al., “Reduced levels of antiinflammatory cytokines in patients with chronic widespread pain,” Arthritis Rheum, 2006;54(8):2656-2664.
[cited by applicant]
Urlaub, G. et al., “Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity,” PNAS, 1980, vol. 77, No. 7, pp. 4216-4220.
[cited by applicant]
Usoskin, D. et al., “Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing,” Nat Neurosci., 2015;18:145-53.
[cited by applicant]
Suthaus, J. et al., “Forced homo- and heterodimerization of all gp130-type receptor complexes leads to constitutive ligand-independent signaling and cytokine-independent growth,” Mol Biol Cell, 2010;21(15):2797-2807.
[cited by applicant]
Vale, M. et al., “Antinociceptive Effects of Interleukin-4, -10, and -13 on the Writhing Response in Mice and Zymosan-Induced Knee Joint Incapacitation in Rats”, The Journal of Pharmacology and Experimental Therapeutics…
[cited by applicant]
Van De Loo, F.A.J. et al., “Gene therapy for rheumatoid arthritis. Lessons from animal models, including studies on interleukin-4, interleukin-10, and interleukin-1 receptor antagonist as potential disease modulators,” …
[cited by applicant]
Van den Bosch, F. et al., “rHuIL-4 in subjects with active rheumatoid arthritis: a phase I dose escalating safety study [abstract],” Arthritis Rheum, 1998;41(Suppl. 9):S56.
[cited by applicant]
Van Hecke O, et al. Chronic pain epidemiology and its clinical relevance. Br J Anaesth 2013;111:13-8.
[cited by applicant]
Van Helvoort, E.M. et al., “Canine IL4-10 fusion protein provides disease modifying activity in a canine model of OA; an exploratory study,” PLoS One. 2019;14(7):e0219587.
[cited by applicant]
Van Helvoort, E.M. et al., “The Role of Interleukin-4 and Interleukin-10 in Osteoarthritic Joint Disease: A Systematic Narrative Review,” Cartilage. 2022;13(2):19476035221098167.
[cited by applicant]
Van Helvoort, E.M. et al., “Effects of the Human IL4-10 Fusion Protein in the Canine Groove Model of Osteoarthritis,” Osteoarthritis and Cartilage, 2017;25:S76-S444.
[cited by applicant]
Van Meegeren, M.E.R. et al., “IL-4 alone and in combination with IL-10 protects against blood-induced cartilage damage,” Osteoarthritis and Cartilage, 2012;20:764-772.
[cited by applicant]
Van Meegeren, M.E.R. et al., “A single intra-articular injection with IL-4 plus IL-10ameliorates blood-induced cartilage degeneration in haemophilic mice”, British Journal of Haematology, 2013, vol. 160, 515-520.
[cited by applicant]
Van Meegeren, M.E.R. et al., “Blood-induced joint damage: novel targets for therapy,” Chapter 8, 2012, pp. 118-131.
[cited by applicant]
Van Meegeren, M.E.R. et al., “The Combination of IL-4 and IL-10 and IL-10 protects against blood cartilage damage,” Osteoarthritis and Cartilage, 2010, vol. 18, Supplement 2, pp. S45-S256.
[cited by applicant]
Van Meegeren, M.E.R., “Blood-induced joint damage: novel targets for therapy”, 2012;1-180.
[cited by applicant]
Van Roon, J.A.G. et al., “Suppression of inflammation and joint destruction in rheumatoid arthritis may require a concerted action of Th2 cytokines,” Current opinion in investigational drugs, 2002;3(7):1011-1016.
[cited by applicant]
Van Roon, J.A.G. et al., “Interleukin 10 treatment of patients with rheumatoid arthritis enhances Fc gamma receptor expression on monocytes and responsiveness to immune complex stimulation,” The Journal of rheumatology,…
[cited by applicant]
Van Roon, J.A.G. et al., “Decrease in Peripheral type 1 over type 2 T ell cytokine production in patients with rheumatoid arthritis correlates with an increase in severity of disease”, Annals of the Rheumatic Diseases, …
[cited by applicant]
Van Roon, J.A.G. et al., “Differentiation of naïve CD4+ T cells towards T helper 2 cells is not impaired in rheumatoid arthritis patients”, Arthritis Res Ther, 2003;5:R269-R276.
[cited by applicant]
Van Roon, J.A.G. et al., “Prevention and Reversal of Cartilage Degradation in Rheumatoid Arthritis by Interleukin-10 and Interleukin-4”, Arthritis & Rheumatism, 1996, vol. 39, No. 5, pp. 829-835.
[cited by applicant]
Van Roon, J.A.G. et al. “Proinflammatory cytokine production and cartilage damage due to rheumatoid synovial T helper-1 activation is inhibited by interleukin-4”, Annals of the Rheumatic Disease, 1995;54:836-840.
[cited by applicant]
Van Roon, J.A.G. et al., “Stimulation of Suppressive T Cell Response by Human but not Bacterial 60-kD Heat-shock Protein in Synovial Fluid of Patients with Rheumatoid Arthritis”, The American Society for Clinical Invest…
[cited by applicant]
Van Roon, J.A.G. et al., “Synergistic Activity of Interleukin-4 and Interleukin-10 in Suppression of Inflammation and Joint Destruction in Rheumatoid Arthritis”, Arthritis & Rheumatish, 2001, vol. 44, No. 1, pp. 3-12.
[cited by applicant]
Van Vulpen, L.F.D. et al., “A Fusion Protein ofInterleukin-4 and Interleukin-10 Protects Against Blood-Induced Cartilage Damage In Vitro and In Vivo,” Journal of Thrombosis and Haemostasis, 2017;15(9): 1788-1798.
[cited by applicant]
Vanderwall, A.G, et al., “Effects of spinal non-viral interleukin-10 gene therapy formulated with d-mannose in neuropathic interleukin-10 deficient mice: Behavioral characterization, mRNA and protein analysis in pain re…
[cited by applicant]
Verhoef, C. M., et al., “Interleukin 10 (IL-10), not IL-4 or interferon-gamma production, correlates with progression of joint destruction in rheumatoid arthritis,” The Journal of rheumatology, 2001;28(9):1960-1966.
[cited by applicant]
Verhoef, C.M. et al., “The immune suppressive effect of dexamethasone in rheumatoid arthritis is accompanied by upregulation of interleukin 10 and by differential changes in interferon and interleukin 4 production”, Ann…
[cited by applicant]
Wang, Y. et al., “A mixed-charge pair in human interleukin 4 dominates high-affinity interaction with the receptor α chain” PNAS, 1997, vol. 94, pp. 1657-1662.
[cited by applicant]
Westerhof, L.B. et al., “3D Domain Swapping Causes Extensive Multimerisation of Human Interleukin-10 When Expressed In Planta,” PLoSONE, 2012, vol. 7, Issue 10, pp. 1-10.
[cited by applicant]
Wijngaarden, S. et al., “A Shift in the Balance of Inhibitory and Activating FCγ Receptors on Monocytes Toward the Inhibitory FCγ Receptor Iib Is Associated with Prevention of Monocyte Activation in Rheumatoid Arthritis…
[cited by applicant]
Willemen, H.L.D.M. et al., “Monocytes/Macrophages control resolution of transient inflammatory pain,” J Pain, 2014;15(5):496-506.
[cited by applicant]
Woolf, C.J. et al., “Neuronal plasticity: increasing the gain in pain,” Science, 2000;288:1765-9.
[cited by applicant]
Yoo, T.J. “Anti-Inflammatory Gene Therapy Improves Spatial Memory Performance in a Mouse Model of Alzheimer's Disease,” J Alzheimers Dis., 2022;85(3):1001-1008.
[cited by applicant]
Yoon, S. et al., “Conformational Changes Mediate Interleukin-10 Receptor 2 (IL-10R2) Binding to IL-10 and Assembly of the Signaling Complex” The Journal of Biological Chemistry, 2006, vol. 281, No. 46, pp. 35088-35096.
[cited by applicant]
Zdanov, A., “Structural analysis of cytokines comprising the IL-10 family,” Cytokine & Growth Factor Reviews, 2010;21:325-330.
[cited by applicant]
Zhang, J. M. , et al, “Cytokines, Inflammation, and Pain”, Department of Anesthesiology and Department of Anesthesiology and Pain Medicine, 2007, vol. 45, No. 2, pp. 26-37.
[cited by applicant]
Pani, G. et al.: MorphoNeuroNet: An automated method for dense neurite network analysis, Cytom Part A. 85(2):188-99 (2014).
[cited by applicant]
Alexander, Guillermo M. et al. Changes in cerebrospinal fluid levels of pro-inflammatory cytokines in CRPS. Pain 116(3):213-219 (2005).
[cited by applicant]
Alexander, Guillermo M. et al. Changes in immune and glial markers in the CSF of patients with complex regional pain syndrome. Brain, behavior, and immunity 21(5):668-676 (2007).
[cited by applicant]
Azari, Pari. et al. Efficacy and safety of ketamine in patients with complex regional pain syndrome: a systematic review. CNS drugs 26:215-228 (2012).
[cited by applicant]
Bean, D. J. et al. Extent of recovery in the first 12 months of complex regional pain syndrome type-1: A prospective study. European journal of pain 20(6):884-894 (2016).
[cited by applicant]
Beerthuizen, Annemerle. et al. Demographic and medical parameters in the development of complex regional pain syndrome type 1 (CRPS1): prospective study on 596 patients with a fracture. Pain 153(6):1187-1192 (2012).
[cited by applicant]
Bharwani, Krishna D. et al. Complex regional pain syndrome: diagnosis and treatment. BJA Education 17(8):262-268 (2017).
[cited by applicant]
Coderre, Terence J. et al. Chronic post-ischemia pain (CPIP): a novel animal model of complex regional pain syndrome-type I (CRPS-I; reflex sympathetic dystrophy) produced by prolonged hindpaw ischemia and reperfusion i…
[cited by applicant]
De Mos, Marieke. et al. Medical history and the onset of complex regional pain syndrome (CRPS). Pain 139(2):458-466 (2008).
[cited by applicant]
De Mos, Marissa. et al. The incidence of complex regional pain syndrome: a population-based study. Pain 129(1-2):12-20 (2007).
[cited by applicant]
Goebel, Andreas. et al. Standards for the diagnosis and management of complex regional pain syndrome: Results of a European Pain Federation task force. European Journal of Pain 23(4):641-651 (2019).
[cited by applicant]
Goebel, Andreas. et al. The Valencia consensus-based adaptation of the IASP complex regional pain syndrome diagnostic criteria. Pain 162(9):2346-2348 (2021).
[cited by applicant]
Goh, En Lin. et al. Complex regional pain syndrome: a recent update. Burns and trauma 5:2, 1-11 (2017).
[cited by applicant]
Goldberg, Michael E. et al. Pharmacodynamic profiles of ketamine (R−) And (S+) with five day inpatient infusion for the treatment of complex regional pain syndrome. Pain physician 13(4):379-387 (2010).
[cited by applicant]
Harden, R. Norman. et al. Complex regional pain syndrome: practical diagnostic and treatment guidelines. Pain medicine 14(2):180-229 (2013).
[cited by applicant]
Harden, R. Norman. et al. Complex regional pain syndrome: practical diagnostic and treatment guidelines. Pain medicine 23(Supplement_1):S1-S53 (2022).
[cited by applicant]
Harden, R. Norman. et al. Validation of proposed diagnostic criteria (the “Budapest Criteria”) for complex regional pain syndrome. Pain 150(2):268-274 (2010).
[cited by applicant]
Hoikkanen, Tomas. et al. Long-term outcome of spinal cord stimulation in complex regional pain syndrome. Neurosurgery 89(4):597-609 (2021).
[cited by applicant]
Lloyd, Emilia C.O. et al. Complex Regional Pain Syndrome. American Family Physician 104(1):49-55 (2021).
[cited by applicant]
Mangnus, Thomas JP. et al. Different types of pain in complex regional pain syndrome require a personalized treatment strategy. Journal of Pain Research:4379-4391 (2023).
[cited by applicant]
Mangnus, Thomas JP. et al. From a symptom-based to a mechanism-based pharmacotherapeutic treatment in complex regional pain syndrome. Drugs 82(5):511-531 (2022).
[cited by applicant]
Milligan, Erin D. et al. Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10. European Journal of Neuroscience 21(8):2136-2148 (2005).
[cited by applicant]
Mogil, Jeffrey S. Animal models of pain: progress and challenges. Nature Reviews Neuroscience 10(4): 283-294 (2009).
[cited by applicant]
Ott, Stephan, and Christian Maihofner. Signs and symptoms in 1,043 patients with complex regional pain syndrome. The Journal of Pain 19(6):599-611 (2018).
[cited by applicant]
Prado, Judith. et al. Cytokine receptor clustering in sensory neurons with an engineered cytokine fusion protein triggers unique pain resolution pathways. Proceedings of the National Academy of Sciences 118(11):e2009647…
[cited by applicant]
Price, Theodore J. et al. Transition to chronic pain: opportunities for novel therapeutics. Nature Reviews Neuroscience 19(7):383-384 (2018).
[cited by applicant]
Raja, Srinivasa N. et al. Complex regional pain syndrome: a comprehensive qualitative research study on unmet needs in the “patient journey”. Journal of Pain Research:2391-2401 (2021).
[cited by applicant]
Sadler, Katelyn E. et al. Innovations and advances in modelling and measuring pain in animals. Nature Reviews Neuroscience 23(2):70-85 (2022).
[cited by applicant]
Sandroni, Paola. et al. Complex regional pain syndrome type I: incidence and prevalence in Olmsted county, a population-based study. Pain 103(1-2):199-207 (2003).
[cited by applicant]
Steen-Louws, Cristine. et al. Sialic Acid-Engineered IL4-10 Fusion Protein is Bioactive and Rapidly Cleared from the Circulation. Pharmaceutical Research 37:1-10 (2020).
[cited by applicant]
Van Velzen, Gijsbrecht AJ. et al. Health-related quality of life in 975 patients with complex regional pain syndrome type 1. Pain 155(3):629-634 (2014).
[cited by applicant]
Zdanov, Alexander. et al. Crystal structure of interleukin-10 reveals the functional dimer with an unexpected topological similarity to interferon γ. Structure 3(6):591-601 (1995).
[cited by applicant]
Dispenza, Melanie C. Classification of Hypersensitivity Reactions. Allergy & Asthma Proceedings 40(6):470-473 (2019).
[cited by applicant]
Intrathecal. National Cancer Institute. Oct. 5, 2024 [retrieved on Oct. 16, 2024]. Available at URL:https://www.cancer.gov/publications/dictionaries/cancer-terms/def/intrathecal pp. 1-2.
[cited by applicant]
Kumar, Krishna. et al. Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology: long-term benefits and efficacy. Surgical Neurology 55(2):79-86 (2001).
[cited by applicant]
Ma, Jun, and Jun Tang. A Review for Dynamics in Neuron and Neuronal Network. Nonlinear Dynamics 89:1569-1578 (2017).
[cited by applicant]
Ursin, Holger. Brain Sensitization to External and Internal Stimuli. Psychoneuroendocrinology 42:134-145 (2014).
[cited by applicant]
U.S. Appl. No. 17/192,183 Office Action dated Jun. 20, 2024.
[cited by applicant]
U.S. Appl. No. 17/504,045 Office Action dated May 14, 2024.
[cited by applicant]
U.S. Appl. No. 17/504,045 Office Action dated Oct. 10, 2024.
[cited by applicant]